Integrated BioPharma (INBP) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 4, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2026, filed Sep 25, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INBP SEC filings page.
Integrated BioPharma Inc (INBP) reported $43.9M in revenue for fiscal year 2026, down 19.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2026’s revenue contraction exposed a thin-margin model: gross profit collapsed while overhead barely changed and liabilities rose.
Operating leverage turned sharply negative: revenue fell from$54.4M to$43.9M , making a modest volume decline disproportionately damaging to earnings. Meanwhile, SG&A declined only1.0% as gross margin fell8.4% percentage points, indicating the prior year’s improvement was not durable scale economics.
Cash conversion diverged from accounting earnings: net income became a loss of
The balance sheet shifted toward obligations: liabilities rose
Financial Health Signals
We do not publish a peer-relative financial health score for Integrated BioPharma Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Integrated BioPharma Inc scores 0.46, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $34.3M against total assets of $25.3M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Integrated BioPharma Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Integrated BioPharma Inc reported a net loss of $2.8M while generating $1.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Integrated BioPharma Inc reported an operating loss of $2.7M against $12K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Integrated BioPharma Inc generated $9.8M in revenue in Q4 2026. This represents a decrease of 30.9% from the same quarter a year earlier. Against the prior quarter it is down 3.1%.
Integrated BioPharma Inc's EBITDA was -$799K in Q4 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 220.5% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Integrated BioPharma Inc reported a net loss of $1.4M in Q4 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Integrated BioPharma Inc earned -$0.04 per diluted share (EPS) in Q4 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Integrated BioPharma Inc recorded an outflow of $1.3M in free cash flow in Q4 2026, representing a cash shortfall after capex. Against the prior quarter it is down 359.8%.
Integrated BioPharma Inc held $4.5M in cash as of Q4 2026; no long-term debt figure is on record for that period.
Not reported for Q4 2026.
Margins & Returns
Integrated BioPharma Inc's gross margin was 0.3% in Q4 2026, indicating the percentage of revenue retained after direct costs. This is down 10.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.0 percentage points.
Integrated BioPharma Inc's operating margin was -8.9% in Q4 2026, reflecting core business profitability. This is down 13.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.9 percentage points.
Integrated BioPharma Inc's net profit margin was -13.9% in Q4 2026, showing the share of revenue converted to profit. This is down 12.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.7 percentage points.
Integrated BioPharma Inc's quarterly ROE was -7.7% in Q4 2026: one quarter's net income over shareholder equity, not annualized. This is down 6.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.3 percentage points.
Capital Allocation
Integrated BioPharma Inc invested $149K in capex in Q4 2026, funding long-term assets and infrastructure. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q4 2026.
Not reported for Q4 2026.
INBP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.8M-30.9% | $10.1M-27.5% | $11.3M-10.6% | $12.7M-6.8% | $14.2M+11.2% | $13.9M+6.1% | $12.6M+9.6% | $13.6M+5.4% |
| Cost of Revenue | $9.8M-23.1% | $10.4M-16.2% | $11.3M-1.7% | $11.7M-4.7% | $12.7M+10.9% | $12.4M+4.2% | $11.4M+4.1% | $12.2M+1.3% |
| Gross Profit | $28K-98.1% | -$276K-117.8% | $29K-97.5% | $1.0M-25.7% | $1.5M+14.4% | $1.6M+24.3% | $1.2M+125.2% | $1.4M+64.8% |
| SG&A Expenses | $897K+1.9% | $809K-0.4% | $943K-2.7% | $856K-2.8% | $880K-0.2% | $812K-9.1% | $969K-0.3% | $881K-0.6% |
| Operating Income | -$869K-247.5% | -$1.1M-246.8% | -$914K-552.5% | $163K-66.7% | $589K+46.5% | $739K+108.2% | $202Kn/m | $490Kn/m |
| EBITDA | -$799K-220.5% | -$1.0M-224.8% | -$836K-393.3% | $240K-58.3% | $663K+39.0% | $815K+88.7% | $285Kn/m | $575K+2400.0% |
| Interest Expense | $124K+63.2% | -$39Kn/m | -$40Kn/m | -$33Kn/m | $76K+31.0% | -$5K-225.0% | -$11Kn/m | -$14Kn/m |
| Income Tax | $516K-33.2% | -$198K-218.6% | -$112K-262.3% | $73K-70.2% | $773K+429.5% | $167K+149.3% | $69Kn/m | $245K+1784.6% |
| Net Income | -$1.4Mn/m | -$837K-237.0% | -$762K-756.9% | $123K-52.5% | -$178K-166.4% | $611K+114.4% | $116Kn/m | $259Kn/m |
| EPS (Basic) | -$0.04n/m | -$0.03-250.0% | -$0.03 | $0.00-100.0% | $0.00-100.0% | $0.02+100.0% | $0.00 | $0.01n/m |
| EPS (Diluted) | -$0.04n/m | -$0.03-250.0% | -$0.03 | $0.00-100.0% | $0.00-100.0% | $0.02+100.0% | $0.01 | $0.01n/m |
| Diluted Shares (Avg) | N/A | 31M-1.4% | 31M | 31M+2.5% | N/A | 32M+2.5% | 31M | 31M+2.3% |
Not reported in any period shown, so not listed: R&D Expenses.
INBP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $25.3M+1.8% | $26.7M+3.9% | $23.5M-8.2% | $25.5M-2.5% | $24.9M-5.0% | $25.7M-4.8% | $25.7M-0.2% | $26.2M-1.7% |
| Current Assets | $17.4M-7.4% | $18.0M-3.1% | $17.8M-1.8% | $19.6M+7.2% | $18.8M+5.0% | $18.5M+1.6% | $18.2M+6.4% | $18.3M+3.1% |
| Cash & Equivalents | $4.5M+23.7% | $5.8M+96.8% | $5.3M+115.9% | $4.7M+108.4% | $3.6M+115.6% | $3.0M+46.6% | $2.5M+236.2% | $2.3M-12.5% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $9.1M-2.3% | $8.1M-19.4% | $8.4M-24.4% | $10.5M-6.7% | $9.4M-16.7% | $10.1M-9.8% | $11.1M-8.9% | $11.2M+6.8% |
| Accounts Receivable | $3.3M-38.6% | $3.7M-28.1% | $3.6M-15.0% | $4.0M-9.2% | $5.4M+16.3% | $5.1M+7.6% | $4.2M+13.3% | $4.4M+5.1% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $7.7M+67.3% | $7.7M+45.8% | $3.8M-85.3% | $5.1M-23.9% | $4.6M-34.2% | $5.3M-34.3% | $25.6M+258.4% | $6.6M-14.5% |
| Current Liabilities | $5.8M+36.6% | $5.5M+11.0% | $3.5M-36.5% | $4.8M-21.0% | $4.2M-30.6% | $5.0M-28.3% | $5.6M-4.4% | $6.0M-2.7% |
| Non-Current Liabilities | $1.9M+456.3% | $2.2M+639.7% | $237K-98.8% | $287K-52.5% | $336K-60.3% | $292K-73.1% | $20.1M+1417.9% | $604K-61.3% |
| Total Equity | $17.7M-13.0% | $19.0M-6.9% | $19.8M+100112.9% | $20.5M+10.5% | $20.3M+5.6% | $20.4M+7.8% | $20K-99.9% | $18.6M-1.8% |
| Retained Earnings | -$34.3Mn/m | -$32.9Mn/m | -$32.1Mn/m | -$31.3Mn/m | -$31.4Mn/m | -$31.2Mn/m | -$31.9Mn/m | -$32.0Mn/m |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
INBP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M-302.0% | $517K-16.1% | $617K+207.0% | $1.3M+98.0% | $591Kn/m | $616K-62.5% | $201Kn/m | $657K-50.0% |
| Depreciation & Amortization | $70K-1.4% | $68K-10.5% | $78K-6.0% | $77K-9.4% | $71K-5.3% | $76K-1.3% | $83K+6.4% | $85K+10.4% |
| Stock-Based Compensation | N/A | N/A | N/A | $49K-7.5% | N/A | N/A | N/A | $53K-25.4% |
| Capital Expenditures | $149K | $0-100.0% | $24K-17.2% | $173K+208.9% | N/A | $116K-66.4% | $29K+20.8% | $56K+47.4% |
| Free Cash Flow | -$1.3M | $517K+3.4% | $593K+244.8% | $1.1M+87.7% | N/A | $500K-61.5% | $172Kn/m | $601K-52.9% |
| Investing Cash Flow | -$149Kn/m | $6Kn/m | -$24Kn/m | -$173Kn/m | -$4Kn/m | -$116Kn/m | -$29Kn/m | -$56Kn/m |
| Financing Cash Flow | -$12K-117.9% | -$11Kn/m | -$11K-161.1% | -$11Kn/m | $67Kn/m | $0n/m | $18Kn/m | -$7K-333.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
INBP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 0.3%-10.1pp | -2.7%-13.8pp | 0.3%-9.0pp | 8.0%-2.0pp | 10.4%+0.3pp | 11.1%+1.6pp | 9.3%+4.8pp | 10.1%+3.6pp |
| Operating Margin | -8.9%-13.0pp | -10.7%-16.0pp | -8.1%-9.7pp | 1.3%-2.3pp | 4.2%+1.0pp | 5.3%+2.6pp | 1.6%+5.5pp | 3.6%+4.0pp |
| Net Margin | -13.9%-12.7pp | -8.3%-12.7pp | -6.8%-7.7pp | 1.0%-0.9pp | -1.3%-3.4pp | 4.4%+2.2pp | 0.9%+4.2pp | 1.9%+2.4pp |
| Return on Equity | -7.7%-6.9pp | -4.4%-7.4pp | -3.9%-591.9pp | 0.6%-0.8pp | -0.9%-2.3pp | 3.0%+1.5pp | 588.0%+590.1pp | 1.4%+1.7pp |
| Return on Assets | -5.4%-4.7pp | -3.1%-5.5pp | -3.2%-3.7pp | 0.5%-0.5pp | -0.7%-1.7pp | 2.4%+1.3pp | 0.4%+1.9pp | 1.0%+1.2pp |
| Current Ratio | 3.00-1.4x | 3.25-0.5x | 5.03+1.8x | 4.12+1.1x | 4.42+1.5x | 3.72+1.1x | 3.26+0.3x | 3.04+0.2x |
| Liabilities-to-Equity | 0.43+0.2x | 0.41+0.1x | 0.19-1299.6x | 0.25-0.1x | 0.23-0.1x | 0.26-0.2x | 1299.81+1299.4x | 0.36-0.1x |
| Asset Turnover | 0.39-0.2x | 0.38-0.2x | 0.480.0x | 0.500.0x | 0.57+0.1x | 0.54+0.1x | 0.490.0x | 0.520.0x |
| FCF Margin | -13.7% | 5.1%+1.5pp | 5.3%+3.9pp | 8.9%+4.5pp | N/A | 3.6%-6.3pp | 1.4%+17.4pp | 4.4%-5.5pp |
Not reported in any period shown, so not listed: Debt-to-Equity.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Integrated BioPharma Inc INBP | FY2026 | $43.9M | -$2.8M | -6.5% | $5.4M | — |
| BAB Inc BABB | FY2025 | $3.4M | $559K | 16.3% | $5.9M | — |
| Limitless X Holdings Inc LIMX | FY2025 | $947K | N/A | N/A | $4.6M | — |
| Cyanotech Corp CYAN | FY2025 | $24.2M | -$3.2M | -13.2% | $3.2M | — |
Where Integrated BioPharma Inc Ranks
Frequently Asked Questions
Integrated BioPharma Inc (INBP) reported $43.9M in total revenue for fiscal year 2026. This represents a -19.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Integrated BioPharma Inc (INBP) revenue declined by 19.3% year-over-year, from $54.4M to $43.9M in fiscal year 2026.
No, Integrated BioPharma Inc (INBP) reported a net loss of $2.8M in fiscal year 2026, with a net profit margin of -6.5%.
Integrated BioPharma Inc (INBP) had EBITDA of -$2.4M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
Integrated BioPharma Inc (INBP) had a gross margin of 1.8% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
Integrated BioPharma Inc (INBP) had an operating margin of -6.2% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
Integrated BioPharma Inc (INBP) had a net profit margin of -6.5% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
Integrated BioPharma Inc (INBP) has a return on equity of -16.1% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
Integrated BioPharma Inc (INBP) generated $895K in free cash flow during fiscal year 2026. This represents a -52.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Integrated BioPharma Inc (INBP) generated $1.2M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
Integrated BioPharma Inc (INBP) had $25.3M in total assets as of fiscal year 2026, including both current and long-term assets.
Integrated BioPharma Inc (INBP) invested $346K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
Integrated BioPharma Inc (INBP) had a current ratio of 3.00 as of fiscal year 2026, which is generally considered healthy.
Integrated BioPharma Inc (INBP) had a liabilities-to-equity ratio of 0.43 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.
Integrated BioPharma Inc (INBP) had a return on assets of -11.2% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
Integrated BioPharma Inc (INBP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $5.4M as of Nov 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Integrated BioPharma Inc (INBP) trades at 0.1x sales, its market capitalization divided by $43.9M revenue, FY2026. The market capitalization is $5.4M as of Nov 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Integrated BioPharma Inc (INBP) has an Altman Z-Score of 0.46, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Integrated BioPharma Inc (INBP) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Integrated BioPharma Inc (INBP) reported a net loss of $2.8M while generating $1.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Integrated BioPharma Inc (INBP) reported an operating loss of $2.7M against $12K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.